Physician profile
Vincent Vess
NPI 1679831317
$3,321.54
in general payments reported to CMS, 2019-2025
23 companies · $18.30 in 2025
The $18.30 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $532 · 2021: $445 · 2022: $345 · 2023: $763 · 2024: $498 · 2025: $18.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,002.97 | 2019-2024 | Grafix Pl, Collagenase Santyl |
| Tactile Systems Technology INC | $208.37 | 2019-2021 | |
| Inari Medical, INC. | $187.32 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Organogenesis INC. | $120.20 | 2021-2022 | |
| Abbott Laboratories | $99.49 | 2021-2023 | Proclaim |
| Misonix INC | $98.73 | 2019-2021 | |
| Celularity INC. | $97.00 | 2019 | |
| Integra Lifesciences Corporation | $86.07 | 2021-2023 | Integra, Surgimend, Omnigraft |
| Abbvie INC. | $63.28 | 2020-2022 | |
| Dermira, INC. | $55.71 | 2019 | |
| Paratek Pharmaceuticals, INC. | $48.06 | 2023 | Nuzyra |
| Biofrontera INC. | $41.79 | 2019-2020 | |
| Urgo Medical North America, LLC | $32.42 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Bioventus LLC | $32.38 | 2020-2023 | Theragenesis Bilayer Wound Matrix |
| Merck Sharp & Dohme LLC | $26.68 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $18.30 | 2025 | Theragenesis Wound Matrix |
| Hartmann USA, INC. | $18.00 | 2023 | Zetuvit Plus |
| Kerecis Limited | $17.16 | 2022 | |
| Biotissue Holdings INC. | $15.81 | 2021 | |
| Csl Behring | $15.22 | 2023 | Kcentra |
| Nabriva Therapeutics, Plc | $12.29 | 2022 | |
| Tei Biosciences INC | $12.15 | 2019 | |
| Polynovo North America LLC | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Vess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.